Cardio Diagnostics Holdings, Inc. announced that the American Medical Association (AMA) has granted and assigned a dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) code, 0439U, for the company's AI-driven coronary heart disease (CHD) event risk assessment test, Epi+Gen CHD. Receipt of this new CPT PLA code, which will be effective on April 1, 2024, is a significant step toward payer billing and payment, facilitating broader adoption of the first and only AI-powered integrated genetic-epigenetic clinical blood test for evaluating the likelihood of a patient experiencing a CHD event, mainly a heart attack, within the next three years. Primary Prevention of Heart attacks: The Clinical and Economic Benefits of Epi+Gen CHD: Every year, about 805,000 people in the United States have a heart attack, with someone experiencing a heart attack every 40 seconds.

Heart disease is the leading cause of death for both men and women. In 2021, heart disease was responsible for the deaths of more than 695,000 Americans. Of those deaths, 310,661 occurred in women, which represents one in every five female deaths.

For employers, this means potentially greater access to a technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks. The company's commitment to making heart disease risk assessment, detection, and management more accessible, personalized, and precise is key to winning the fight against the leading cause of death in the United States.